Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Statin and bisphosphonate treatment in low-risk Philadelphia-negative myeloproliferative neoplasms
2016-001406-42Phase 2Terminated
- Sponsor
- Department of Haematology, Zealand University Hospital
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of atorvastatin and zoledronic acid in thrombocythemia, polycythemia vera (PV), primary myelofibrosis (PMF) and 1 more (4 arms), sponsored by Department of Haematology, Zealand University Hospital. Primary endpoint: Inflammatory biomarkers. Started Apr 2016; status: terminated.
02
Drugs
atorvastatinzoledronic acid
03
Conditions
thrombocythemiapolycythemia vera (PV)primary myelofibrosis (PMF)myeloproliferative neoplasm
Beyond the preview
Go deeper on 2016-001406-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001406-42.